

Table 1: Baseline characteristic and change during Evolocumab treatment period.

	Before evolocumab n=13	On evolocumab n=13	Change	P-value
Weight (kg)	82.7 ± 15.9	82.8 ± 15	0.1 ± 1.3 (+0.1 %)	0.31
BMI (kg/m ²)	29.4 ± 4	29.4 ± 3.7	0.1 ± 0.4 (+0.2 %)	0.31
Lipids and lipoproteins				
Cholesterol (mmol/l)	3.9 ± 0.5	2.3 ± 0.6	-1.7 ± 0.4 (-42 %)	<0.001
HDL-C (mmol/l)	1.4 ± 0.4	1.6 ± 0.4	0.2 ± 0.2 (+16 %)	0.0033
Triglycerides (mmol/l)	1.6 ± 0.5	1.3 ± 0.5	-0.2 ± 0.6 (-14 %)	0.19
LDL-C (mmol/l)	1.7 ± 0.4	0.4 ± 0.2	-1.4 ± 0.4 (-78 %)	<0.001
LDL size (nm)	25.6 ± 1.5	25.7 ± 1.3	-0.1 ± 0.9 (-0.4 %)	0.62
ApoC-III (mg/dl)	12.2 ± 4.3	10.4 ± 5.2	-1.9 ± 3.7 (-15 %)	0.022
ApoB (mg/dl)	75.9 ± 14.5	35.3 ± 10.9	-40.5 ± 8.8 (-53 %)	<0.001
ApoB48 (mg/l)	6.1 ± 3.8	5.3 ± 3.3	-0.8 ± 2.5 (-13 %)	0.38
Lp(a) (mg/dl)	29.8 ± 29.9	22.7 ± 25.7	-7.2 ± 6.4 (-24 %)	<0.001
ApoE (mg/dl)	3.0 ± 0.7	2.0 ± 0.5	-1 ± 0.6 (-33 %)	<0.001
ApoA-I (mg/dl)	142 ± 25.1	151 ± 25.7	9.5 ± 11.3 (+7 %)	0.011
TRL-C (mg/dl)	33.4 ± 10.9	17.8 ± 6.5	-15.6 ± 7.8 (-47 %)	<0.001
RLP-C (mg/dl)	8.5 ± 4.3	7.1 ± 4.7	-1.4 ± 4.5 (-17 %)	0.24
ANGPTL3 (ng/ml)	240 ± 45	246 ± 58	-5.6 ± 48 (+2 %)	0.79
Hepatic lipid metabolism				
DNL (%)	17.6 ± 12.8	17.1 ± 11.7	-0.5 ± 13 (-3 %)	0.95
NEFA (umol/l)	615 ± 207	608 ± 181	-7.2 ± 190 (-1 %)	0.64
β-OHB (mg/dl)	0.7 ± 0.2	0.7 ± 0.3	0.1 ± 0.3 (+8 %)	0.59
Liver fat (%)	6.6 ± 6.6	6.3 ± 7.2	-0.2 ± 1.1 (-3 %)	0.43

Data are shown as mean ± SD. P-values have been calculated using the Wilcoxon signed-rank test. Biomarkers were analysed in fasting samples taken at the day of the kinetic study, before and after the 12 weeks evolocumab treatment period. Data have partly been published earlier (see reference³³).